Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
44
LAB Quote, Financials, Valuation and Earnings
Last price:
$1.48
Seasonality move
:
10.63%
Day range:
$1.42 - $1.51
52-week range:
$0.92 - $2.14
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
4.32x
P/B ratio:
1.41x
Volume:
750.2K
Avg. volume:
1.9M
1-year change:
-19.67%
Market cap:
$565.3M
Revenue:
$174.4M
EPS (TTM):
-$0.34
Analysts' Opinion
-
Consensus RatingStandard BioTools, Inc. has received a consensus rating of Hold. The company's average rating is a Hold based on 1 Buy rating, 2 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $1.65, Standard BioTools, Inc. has an estimated upside of 5.44% from its current price of $1.47.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $1.55 representing 100% downside risk from its current price of $1.47.
Fair Value
-
According to the consensus of 3 analysts, Standard BioTools, Inc. has 5.44% upside to fair value with a price target of $1.65 per share.
LAB vs. S&P 500
-
Over the past 5 trading days, Standard BioTools, Inc. has underperformed the S&P 500 by -6.5% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Standard BioTools, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Standard BioTools, Inc. revenues have been falling on a year-over-year basis for 3 quarters in a row. In the most recent quarter Standard BioTools, Inc. reported revenues of $19.6M.
Earnings Growth
-
Standard BioTools, Inc. earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Standard BioTools, Inc. reported earnings per share of -$0.09.
Enterprise value:
397.8M
EV / Invested capital:
0.93x
Price / LTM sales:
4.32x
EV / EBIT:
--
EV / Revenue:
3.09x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-4.04x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$59.9M
Return On Assets:
-18.43%
Net Income Margin (TTM):
-84.97%
Return On Equity:
-24.44%
Return On Invested Capital:
-22.34%
Operating Margin:
-120.02%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $105.2M | $118.3M | $128.8M | $22.1M | $19.6M | |
| Gross Profit | $48M | $60M | $59.9M | $12.1M | $9.5M | |
| Operating Income | -$70.4M | -$94.7M | -$107.2M | -$19.3M | -$23.5M | |
| EBITDA | -$55.5M | -$83.6M | -$95.5M | -$18.3M | -$21.9M | |
| Diluted EPS | -$0.96 | -$0.71 | -$0.34 | -$0.07 | -$0.09 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $73.5M | $229M | $170.7M | $453.6M | $472.4M | |
| Total Assets | $282.2M | $414.9M | $339.3M | $681.5M | $539.6M | |
| Current Liabilities | $47.3M | $46.2M | $51.8M | $120.6M | $108M | |
| Total Liabilities | $182.9M | $477.7M | $471M | $192.2M | $140M | |
| Total Equity | $99.3M | -$62.7M | -$131.7M | $489.3M | $399.7M | |
| Total Debt | $102.2M | $410.8M | $407M | $83.4M | $22.3M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$48.4M | -$143.5M | -$87.2M | -$27.9M | -$22.2M | |
| Cash From Investing | $73.6M | $324.3M | $61.2M | -$30.9M | -$6.7M | |
| Cash From Financing | -$6.1M | -$49.1M | -$54.6M | -$2K | -$112K | |
| Free Cash Flow | -$51.9M | -$148.5M | -$98.4M | -$30.1M | -$23.1M | |
LAB
Sector
Market Cap
$565.3M
$28.1M
Price % of 52-Week High
68.69%
51.39%
Dividend Yield
0%
0%
Shareholder Yield
2.37%
-1.49%
1-Year Price Total Return
-19.67%
-17.13%
Beta (5-Year)
1.236
0.518
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$1.56
200-day SMA
Buy
Level
$1.25
Bollinger Bands (100)
Buy
Level
1.22 - 1.44
Chaikin Money Flow
Sell
Level
-125.4M
20-day SMA
Sell
Level
$1.49
Relative Strength Index (RSI14)
Buy
Level
50.88
ADX Line
Buy
Level
26.03
Williams %R
Buy
Level
-83.3333
50-day SMA
Buy
Level
$1.35
MACD (12, 26)
Buy
Level
0.06
25-day Aroon Oscillator
Buy
Level
88
On Balance Volume
Neutral
Level
305M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (0.2743)
Sell
CA Score
(Annual)
Level (-0.7973)
Sell
Beneish M-Score
(Annual)
Level (-2.1505)
Buy
Momentum Score
Level (3)
Sell
Ohlson Score
Level (0.5647)
Buy
Piotroski F Score
(Annual)
Level (4)
Buy
Quality Ratio Score
Level (5)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Standard BioTools Inc. engages in the provision of biotechnology tools and services for clinical research. It sells preparatory and analytical instruments for mass cytometry, polymerase chain reaction, library prep, single cell genomics, and consumables including integrated fluidic circuits (IFCs), assays, and reagents. The company was founded by Stephen D. Quake and Gajus Vincent Worthington on May 19, 1999 and is headquartered in Boston, MA.
Stock Forecast FAQ
In the current month, LAB has received 1 Buy ratings 2 Hold ratings, and 0 Sell ratings. The LAB average analyst price target in the past 3 months is $1.65.
-
Where Will Standard BioTools, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Standard BioTools, Inc. share price will rise to $1.65 per share over the next 12 months.
-
What Do Analysts Say About Standard BioTools, Inc.?
Analysts are divided on their view about Standard BioTools, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Standard BioTools, Inc. is a Sell and believe this share price will drop from its current level to $1.55.
-
What Is Standard BioTools, Inc.'s Price Target?
The price target for Standard BioTools, Inc. over the next 1-year time period is forecast to be $1.65 according to 3 Wall Street analysts, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 2 analysts rate the stock a Hold.
-
Is LAB A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Standard BioTools, Inc. is a Hold. 2 of 3 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of LAB?
You can purchase shares of Standard BioTools, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Standard BioTools, Inc. shares.
-
What Is The Standard BioTools, Inc. Share Price Today?
Standard BioTools, Inc. was last trading at $1.48 per share. This represents the most recent stock quote for Standard BioTools, Inc.. Yesterday, Standard BioTools, Inc. closed at $1.47 per share.
-
How To Buy Standard BioTools, Inc. Stock Online?
In order to purchase Standard BioTools, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get LAB Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
LAB
Sector
P/E ratio
--
23.89x
PEG ratio
--
-0.01x
P/B ratio
1.41x
1.81x
Price / LTM sales
4.32x
1.59x
Growth Metrics
LAB
Sector
Revenue growth
-11.47%
4.62%
Earnings growth
-24.97%
11.06%
Revenue (5-year growth)
8.27%
6.5%
Earnings forecast
-$0.02
-$0.21
Profitability
LAB
Sector
Profitability FY 2024
$76M
$3.6M
Return on invested capital
-22.34%
-31.84%
Return on assets
-18.43%
-27.96%
Return on equity
-24.44%
-37.63%
Earnings Date
Last Earnings Date
Nov
4
Next Earnings Date
Feb
25
Estimated Next Earnings Date
Feb
3
Balance Sheet
LAB
Sector
Total cash
$194.9M
$26.4M
Short term investments
$126.1M
$25.7M
Total assets
$612.3M
$76.9M
Long term debt
$22.3M
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
87
HUT alert for Dec 25
Hut 8 Corp. [HUT] is up 0.65% over the past day.
Buy
80
TVTX alert for Dec 25
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Buy
60
GPCR alert for Dec 25
Structure Therapeutics, Inc. [GPCR] is down 2.36% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
